SER - NYSE
Serina Therapeutics, Inc.
$5.00
+0.0000%Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
At a Glance
Live SnapshotSerina Therapeutics, Inc. Management Team
Dr. Randall W. Moreadith M.D., Ph.D.
Chief Development Officer
Compensation
$433,880
Mr. Steven A. Ledger
Chief Executive Officer & Director
Compensation
$471,199
Mr. Gregory S. Curhan
Chief Financial Officer
Compensation
$252,663
Dr. J. Milton Harris Ph.D.
Co-Founder, Director Emeritus & Chair of Scientific Advisory Board
Compensation
$26,504
Dr. Balkrishan Gill Ph.D.
Executive Chairman
Compensation
$215,833
Dr. Srini Tenjarla
Senior Vice President of Chemistry, Manufacturing & Controls and Formulation
Compensation
$261,328
Serina Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have sold $706K worth of SER shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
17.3K
87.24K
-87K
-$87K
9-12 Months
0
0.00
99.7K
618.27K
-618K
-$618K
Top Buyers
No buying activity
Top Sellers
Moreadith Randall
Officer: Chief Scientific Officer
$706K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $706K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
1 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
SER - Filing history and reports
No SEC filings available for SER
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.